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SYSTEMATIC REVIEW AND META-ANALYSIS
Bias and Loss to Follow- Up in 
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BACKGROUND: Loss to follow- up (LTFU) is common in randomized controlled trials. However, its potential impact on primary 
outcomes from cardiovascular randomized controlled trials is not known.
METHODS AND RESULTS: We conducted a prospective systematic review (PROSPERO: CRD42019121959) for randomized 
controlled trials published in 8 leading journals over 5 years from January 2014 to December 2018. Extent, reporting, and 
handling of LTFU data were recorded, and the proportion of a trial’s primary outcome results that lose statistical significance 
was calculated after making plausible assumptions for the intervention and control arms. These assumptions could drive dif-
ferential treatment effects between the groups considering relative event incidence between LTFU participants and those in-
cluded in the primary outcome. We identified 117 randomized controlled trials of which 91 (78%) trials reported LTFU, 23 (20%) 
reported no LTFU, and 3 (3%) trials did not report on whether LTFU occurred. The median percentage of study participants 
lost to follow- up was 2% (interquartile range, 0.33%–5.3%). Only 10 trials (9%) had a low cluster of risk factors for impairment 
in trial quality. The percentage of trials losing statistical significance varied from 2% when the relative event incidence for LTFU 
between the randomized groups was 1 for the intervention arm and 1.5 for the control arm to 16% when the relative event 
incidence was 3 for the intervention arm and 1 for the control arm.
CONCLUSIONS: Almost 1 in 6 (16%) cardiovascular randomized trials published in leading journals may have a change in the 
primary outcome if plausible assumptions are made about differential event rates of participants lost to follow up. There is 
scope for improvement arising from LTFU in randomized trials in cardiovascular medicine.
REGISTRATION: URL: https://www.crd.york.ac.uk/prospero; Unique identifier: CRD42019121959.
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The gold standard assessment of a medical in-tervention involves assessment in a randomized controlled trial (RCT).1,2 Randomization balances 
the distribution of any known or unknown potential 
confounding factors between treatment arms.2 This 
mitigates the possibility of selection bias, especially 
if the participants’ group allocations are concealed.3 
Blinding of patients, therapists, and outcome asses-
sors is an additional useful tool to prevent bias.4,5 
Open- label clinical trials are often unavoidable if 
blinding of patients and therapists is not possible.6 
Clinical guidelines may be influenced by biased clinical 
evidence leading to undesirable impacts on patients, 
healthcare providers, and funders.
Up to 80% of contemporary clinical RCTs fail to 
achieve complete follow- up.7–9 This important fac-
tor may affect the integrity of study conclusions. If 
participants are lost and the characteristics of such 
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participants associate with clinical events, then bias 
can arise. This is particularly relevant in open- label 
studies in which assessors know the group allocations 
of the participants. Loss to follow- up (LTFU) in this sce-
nario could favor the intervention arm and neutralize 
the benefit of randomization.10 It is plausible that attri-
tion bias associated with LTFU drives either overesti-
mation or underestimation of treatment effects.11,12
Classification of LTFU and recommendations for 
dealing with LTFU have been made.13 Crucially, how-
ever, the contemporary prevalence and effects of 
LTFU within cardiovascular trials is not known. This 
prospective systematic review and meta- analysis was 
designed to analyze the prevalence and potential im-
pact of LTFU in cardiovascular RCTs. The primary aim 
was to assess the proportion of trials in which the 
primary efficacy end point would change if plausible 
assumptions were made about participants who were 
unaccounted for in the original analysis. In addition, we 
assessed estimates of treatment effect according to 
the extent, reporting, and handling of LTFU and trial 
characteristics associated with LTFU.
METHODS
Eligibility
All supporting data are available within the article and 
its online supplementary files. Ethics approval was not 
required. We predefined reports as being eligible for 
inclusion in this analysis if an RCT in cardiovascular 
disease was described and published in one of the 5 
leading general medical journals and 3 cardiology jour-
nals with the highest impact factors (Annals of Internal 
Medicine, BMJ, JAMA, Lancet, New England Journal 
of Medicine, Circulation, European Heart Journal, and 
Journal of the American College of Cardiology). A 5- 
year publication period was set from 2014 to 2018. An 
additional inclusion criterion was if a patient- important 
binary primary outcome was statistically significant at 
a 2- sided α of 0.05. The rationale behind focusing on 
statistically significant trials in major journals only is that 
the results of these trials are most likely to influence 
clinical guidelines. Therefore, a change in significance 
of a risk ratio due to bias might affect patient care to 
an important extent. Cluster trials, crossover trials, N- 
of- 1 trials, and trials reported in research letters were 
excluded. Equivalence and noninferiority studies were 
excluded unless the authors prespecified testing for 
superiority. Reports describing secondary analyses of 
randomized trials were excluded.
A patient- important outcome was defined as an 
outcome that would be undesirable for a patient to ex-
perience and the patient would thus try to prevent it by 
undergoing an effective treatment. Mortality and mor-
bidity are examples of outcomes that were included. 
Surrogate outcomes were considered as nonpatient 
important (Data S1). The protocol was registered on 
PROSPERO (CRD42019121959).
Literature Search
Reports of RCTs were identified from Medline and 
Embase using OVID (Data S2). The search was re-
stricted to clinical RCTs in cardiovascular disease 
published in the selected journals between 2014 and 
2018. Trials were considered statistically significant if 
the 2- sided 95% CI of an estimate of the relative risk 
did not include 1.0 or if the 2- sided P value for supe-
riority was <0.05 when no CI was reported. A calibra-
tion exercise was performed before the search. One 
reviewer identified and reviewed the potentially eligible 
reports based on an agreed screening form (Data S3). 
The list of included and excluded reports was pro-
vided to the 2- person reviewer team after screening. 
Disagreements were resolved by consensus, with the 
assistance of a third reviewer as required.
CLINICAL PERSPECTIVE
What Is New?
• More than three quarters of cardiovascular 
randomized controlled trials have participants 
who are lost to follow-up. Statistical handling of 
these data vary widely.
• Up to 1 in 6 trials may have a change in the 
primary outcome if plausible assumptions are 
made about differential event rates of partici-
pants lost to follow up.
What Are the Clinical Implications?
• In dealing with loss to follow-up (LTFU), preven-
tion should be prioritized; otherwise, estimation 
can be made by using the worst assumption.
• When reporting LTFU, authors should provide 
baseline characteristics of LTFU participants, 
extent of follow-up before exclusion, and time 
of dropout and should address implication of 
LTFU when interpreting results.
• Inadequate allocation concealment is an inde-
pendent factor associated with LTFU and may 
drive differential treatment effects.
Nonstandard Abbreviations and Acronyms
LTFU loss to follow-up
RCT randomized controlled trial
RI   relative event incidence among those lost 
to follow-up to the event incidence among 
those followed up
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Data Collection
Data were extracted based on an agreed data extrac-
tion form (Data S4). The primary outcome selected for 
the review was the one specified within the report. If the 
report specified both significant primary efficacy and 
safety outcomes, the primary efficacy outcome was 
selected. If multiple primary outcomes were specified, 
the statistically significant outcome in the highest cat-
egory on the outcome hierarchy was selected (Data S1). 
If both intention- to- treat and per- protocol analyses were 
reported, we considered the statistical significance of 
the former; if both unadjusted and adjusted analyses 
were reported, the statistical significance of the former 
was considered. Data on study background, general 
characteristics, methodological quality,14 the extent of 
LTFU, its reporting, and its handling in the analysis re-
lated to the primary outcome were extracted. Patients 
were considered as LTFU if they were mistakenly rand-
omized with inappropriate postrandomization exclusion; 
did not receive the intervention or adhere to treatment, 
with inappropriate postrandomization exclusion; with-
drew consent; crossed over to another arm but were 
not included in the analysis; or lost contact.15 Trials were 
categorized by subspecialty focus: electrophysiology, 
heart failure, interventional cardiology, cardiac surgery, 
general cardiology, and cardiovascular imaging.
Statistical Analysis
The analysis is explained in more detail in the online sup-
plement (Data S5). Methodological and reporting quality 
of the included trials was assessed, as suggested by 
Bikdeli et al14 and the Cochrane risk- of- bias assessment 
tool.16 The extent of LTFU was calculated as the per-
centage of LTFU in each trial from each arm (interven-
tion and control). The ratio of LTFU rate to primary event 
rate was also reported. A univariable random- effects 
metaregression analysis was conducted using the log 
odds of participants lost to follow- up as the dependent 
variable and general trial characteristics and methodo-
logical characteristics as independent variables.
The potential impact of LTFU on the primary out-
come analysis was evaluated by making assumptions 
about the outcomes in LTFU participants (Data S6). 
An estimation algorithm proposed by Akl et  al17 was 
adopted with relative incidence of outcomes in LTFU 
patients compared with patients who were followed- up 
(RILTFU/FU), ranging from 1 to 3. In addition, the follow-
ing common assumptions were used for calculations: 
none of the participants lost to follow- up had the event; 
all participants lost to follow- up had the event; none of 
those lost to follow- up in the treatment group had the 
event, and all those lost to follow- up in the control group 
did (best case scenario); all participants lost to follow- up 
in the treatment group had the event and none of those 
in the control group did (worst- case scenario).
For each trial, 2×2 tables were constructed for the 
collected data for the calculation of risk ratios associ-
ated with each assumption. The percentage of trials 
with their primary outcome becoming nonsignificant 
was calculated based on the assumptions and defi-
nition of statistical significance reported above. Trials 
with no LTFU were excluded in the primary analysis 
but included in a sensitivity analysis. An additional 
prespecified sensitivity analysis stratified by type of 
intervention was conducted. Paired differences in 
Figure 1. Search and screening approach. 
Flow of trial reports identified and screened in this analysis is shown. The search recovered 3668 
reports; 1873 reports were screened after removing duplicates; 117 reports were included after 
screening, and reasons for exclusion are stated in text. FLUKE indicates Follow Up Loss Effect 
Upon Skewing Evidence.
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proportions between interventional cardiology trials 
and those of other cardiology subspecialties were also 
assessed based on different assumptions.
Table 1. General Characteristics of 117 Included Trials in 
the Study (n=117)
No. (%)
Extent of loss to follow- up (overall)
 <1% 34 (38)
 1% to ≤2.5% 19 (21)
 2.5 to ≤5% 14 (15)
 5% to ≤7.5% 9 (10)
 7.5% to ≤10% 3 (3)
 >10% 12 (13)
Cardiology subspecialty
 Electrophysiology 22 (19)
 Heart failure 3 (3)
 Interventional cardiology 33 (28)
 Open heart surgery 4 (3)
 General cardiology* 51 (44)
 Cardiovascular imaging 4 (3)
Control
 Standard care 18 (15)
 Placebo 31 (27)
 Pharmacological 28 (24)
 Surgical/interventional 36 (31)
 Other 4 (3)
Funding
 Private for profit 58 (50)
 Private not for profit 21 (18)
 Governmental 24 (20)
 Not reported 13 (11)
 Not funded 1 (1)
Reporting of methods to deal with LTFU
 Reported in methods 100 (86)
 Reported in results 1 (1)
 No 16 (14)
Among the trials that LTFU occurred (n=91)†
 Separately reported in 2 arms 70 (77)
 Compared the LTFU group baseline characteristics with not 
LTFU
0 (0)
 Implication of LTFU discussed 6 (7)
Analytical method to handle LTFU
 No LTFU occurred 26 (22)
 Complete case analysis‡ 10 (8)
 Worst- case scenario 2 (2)
 Multiple imputation 2 (2)
 Inverse probability weighting 0 (0)
 Censored at time of LTFU in time- to- event analysis 75 (64)
 Assumption that none of the LTFU participants have event 2 (2)
CONSORT diagram
 Without the diagram 32 (27)
CONSORT indicates Consolidated Standards of Reporting Trials; LTFU, loss 
to follow- up.
*General cardiology trials in this review referred to pharmacological trials and 
lifestyle- changing trials.
†Number shown refers to trials that did the following.
‡Complete case analysis is defined as an analysis that only include patients 
with complete outcome data. LTFU patients are excluded from the whole analysis.
Table 2. Methodological and Reporting Quality 
Assessment of the Included Trials
Factors
Trials at Risk of Bias (n=117), 
No. (%)
Inadequate allocation sequence 
concealment*
63 (54)
No blinding of patients† 76 (65)
Early stop 9 (8)
Not using intention- to- treat analysis‡ 29 (25)
Absence of protocol§ 31 (26)
Without explicit statement about 
status of LTFU
43 (36)
LTFU indicates loss to follow- up.
*Allocation concealment defined as to the person enrolling participants 
does not know in advance which treatment the next person will get which 
usually involves the use of computer algorithms. It seeks to prevent selection 
bias by protecting the assignment sequence until allocation, and can always 
be successfully implemented.136 It is considered to be adequate according to 
the definition reported by Jüni et al.3
†Blinding defined as to the withholding information about the assigned 
interventions from people involved in the trial who may potentially be influenced by 
this knowledge; blinding is performed to prevent performance and ascertainment 
bias by protecting the sequence after allocation and cannot always be 
implemented.136,137 It is considered to be adequate only if clearly indicated.
‡Intention to treat analysis defined as an analysis that included all 
randomized participants in the analysis who are all retained in the group to 
which they were allocated.3,136
§Consider as absence if the protocol is not published before or is included 
as appendix beside the main report.
Figure 2. Distribution of trials according to methodological 
and reporting quality assessments that might impair the 
outcomes of the trial. 
Distribution of trials according to the number of methodological 
and reporting quality characteristics (methodological confounders) 
they possess after the assessment: 9% of the trials had none of 
the methodological confounders (n=10), 21% of the trials possessed 1 
methodological confounder (n=24), 32% of the trials possessed 2 major 
methodological confounders (n=38), and 26% of the trials possessed 
3 major methodological confounders (n=30). In addition, 12% of the 
trials had >3 methodological confounders. This list of methodological 
confounders analyzed included the following: (1) inadequate allocation 
sequence concealment, (2) no blinding of patients, (3) early stop of 
trial, (4) not using intention- to- treat analysis, (5) absence of protocol, 
and (6) no explicit statement about status of loss to follow- up.
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RESULTS
After excluding duplicates and screening for eligibility, 
117 studies were included from a total of 3668 from 
the initial search (Figure 1). The list of the 117 studies 
included in this analysis is provided in Table S1.18–134  
The mean age of 407 229 study participants was 
64.2 years (30% female). The trial subspecialties were 
electrophysiology (19%) heart failure (3%), interven-
tional cardiology (28%), cardiac surgery (3%), general 
cardiology (44%), and cardiovascular imaging (3%). 
Baseline study characteristics of the included trials are 
reported in Table 1.
Assessment of the Methodological 
Quality of the Trials
The analytical methods that were used for handling 
LTFU in the primary analysis of the included trials are 
presented in Table 1. The most commonly used method 
Table 3. Regression Analysis Exploring the Association Between the Percentage of LTFU Participants and General and 
Methodological Trial Characteristics
Trial Characteristic
No. of Trials 
(n=117) No. of Patients Odds Ratio (95% CI) P for Interaction
Number of centers 0.098
 1 17 57 048 1.00 (Reference)
 2–10 26 19 680 1.43 (0.56–3.65)
 11–50 34 60 940 2.24 (0.94–5.37)
 >50 40 259 600 1.99 (0.86–4.57)
Sample size 0.039
 ≤500 43 10 971 1.00 (Reference)
 >500–1000 25 17 722 0.97 (0.45–2.05)
 >1000–5000 26 53 077 0.74 (0.36–1.51)
 >5000 23 315 498 0.50 (0.24–1.02)
Concealment of allocation 0.001
 Yes 54 153 572 1.00 (Reference)
 No 63 243 696 2.37 (1.42–3.97)
Blinding of patients 0.15
 Yes 41 288 784 1.00 (Reference)
 No 76 108 484 1.49 (0.86–2.59)
Intention to treat 0.89
 Yes 88 347 413 1.00 (Reference)
 No 29 49 855 1.04 (0.57–1.90)
Length of follow- up, mo 0.002
 ≤6 27 30 234 1.00 (Reference)
 >6 to 12 35 50 278 1.89 (0.87–4.10)
 >12 to 24 26 67 459 2.53 (1.12–5.72)
 >24 29 249 297 3.42 (1.57–7.42)
Trial stopped early 0.75
 Yes 9 66 577 1.00 (Reference)
 No 108 330 691 1.16 (0.46–2.90)
Surgery or interventional 
treatment
0.010
 Yes 52 51 574 1.00 (Reference)
 No 65 345 694 0.50 (0.30–0.85)
General cardiology 0.84
 Yes 51 335 302 1.00 (Reference)
 No 66 61 966 1.06 (0.63–1.77)
Commercial funding 0.78
 Yes 58 299 427 1.00 (Reference)
 No 59 97 841 1.08 (0.63–1.83)
LTFU indicates loss to follow- up.
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was censoring at time of LTFU in a time- to- event analy-
sis (N=75; 64%). Two trials (2%) assumed that no LTFU 
participants experienced events, whereas 10 (8%) used 
complete case analysis and 2 (2%) used a worst- case 
scenario in which only the control arm had events. Two 
trials (2%) used multiple imputation, whereas none re-
ported using inverse probability weighting.
Regarding the reporting of LTFU, 85 (73%) 
used a Consolidated Standards of Reporting Trials 
(CONSORT) diagram. Seventy (77%) trials reported 
Figure 3. Distribution and difference in proportion of LTFU between the intervention and 
control arms among 91 trials with LTFU. 
Distribution of LTFU proportions among 91 trials that reported LTFU stratified by intervention and 
control. A median of 2% LTFU occurred in both the intervention and control arms. The difference 
is not significant (95% CI, −0.48% to 0.53%; P=0.978). Diff indicates difference; LTFU, loss to 
follow- up.
P=0.978
(Diff: 95%CI: -0.48% to 0.53%)
Median
2% 2%
Figure 4. Distribution and difference in ratio of LTFU to events between the intervention 
and control arms among 91 trials with LTFU.
Distribution of ratios across 91 trials with LTFU stratified by intervention and control. Medians 
of 0.12 from intervention arms and 0.11 from control arms indicate that ≈1 person was lost when 
10 experienced events in both intervention and control arms. This shows the relativeness of 
proportions in between LTFU and events. The difference in ratio was not significant (95% CI, 
−0.046 to 0.021; P=0.473). Diff indicates difference; LTFU, loss to follow- up.
P=0.473
(Diff: 95%CI: -0.046 to 0.021)
Median
0.12 0.11
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that LTFU occurred in the intervention and control 
arms separately. However, none of the trials compared 
baseline characteristics of LTFU participants with 
followed- up participants. The implications of LTFU are 
discussed in 6 trials (7%).
Table 2 and Figure 2 demonstrated the number 
of trials meeting the characteristics (methodologi-
cal confounders) for impairment in the quality of 
trial design. Allocation concealment was adequate 
in 54 trials (46%). Patients were blinded adequately 
in 41 trials (35%). In 9 trials (8%), enrollment was 
discontinued prematurely. Twenty- nine trials used 
an intention- to- treat analysis (25%). Thirty- one tri-
als (26%) provided a protocol. Forty- three trials 
(36%) did not state the status of LTFU explicitly in 
the report. Only 10 trials (9%) were free from any 
methodological confounders that might impair the 
methodological quality.
Random- effects metaregression analysis (Table  3) 
suggested that inadequate or unclear concealment of 
allocation was associated with an increase in odds of LTFU 
(odds ratio, 2.37 [95% CI, 1.42–3.97]; P=0.001). Increasing 
sample size (P=0.039) and duration of follow- up (P=0.002) 
also increased the odds of LTFU. Finally, the odds of LTFU 
was decreased in nonsurgical or noninterventional trials 
(odds ratio, 0.50 [95% CI, 0.30–0.85]; P=0.01).
Table 4. Percentage of 91 Trials in Which Results Would 
Lose Significance Under Different Assumptions on the 
Outcomes of LTFU Participants in Intervention and Control 
Arms
N=91
RILTFU/FU (Control) *
3 2 1.5 1
RILTFU/FU (intervention)*
1 3 3 2 4
1.5 3 2 3 4
2 4 3 4 12
3 3 9 10 16
Among the 91 trials, percentages of results that would lose significance under 
less plausible assumptions: (1) none of the LTFU participants had the event, 4%; 
(2) all the LTFU participants had the event, 11%; (3) none of those lost to follow- up 
in the treatment group had the event, and all those lost to follow- up in the control 
group did (best case scenario), 3%; (4) all participants lost to follow- up in the 
treatment group had the event, and none of those in the control group did (worst 
case scenario), 33%. FU indicates follow- up; LTFU, loss to follow- up.
*RILTFU/FU is the relative event incidence among those with LTFU compared 
with those followed up.
Figure 5. Bias and loss to follow- up in randomized controlled trials in cardiovascular medicine.
Assumptions being made toward the outcome of LTFU in each trial from the search and the subsequent calculation made. In total, 117 
trials from 8 journals covering 407 229 patients from 2014 to 2018 were recovered. Assume participants were randomized to intervention 
and control, respectively; 3 had events from each arm and 3 dropouts from each arm. From the figure, dotted transparent figures denote 
LTFU participants, whereas red dotted figures denote LTFU participants being assumed with event. The plausible assumptions being 
made toward the LTFU was based on relative event incidence and a formula detailed in Data S6. The number of events were assumed 
based on the reported formula with incidence ranging from 1 to 3. Calculations of how many trials’ relative risks lost significance after 
making the assumptions were run subsequently. Ann of Intern Med, Annals of Internal Medicine; Eur Heart J, European Heart Journal; 
JACC, Journal of the American College of Cardiology; LTFU, loss to follow- up; NEJM, New England Journal of Medicine.
Intervention Control
Intervention : Control Event 
Ratio (1:3)
Intervention Control
Intervention : Control Event 
Ratio (1:1)
Intervention Control
Intervention : Control Event 
Ratio (3:1)
Intervention : Control 
Event Ratio (1:3)
3%
Randomized
Controlled Trials
(Cardiology)
Plausible 
Assumptions on 
Events
Proportion of Trials 
Losing Signiicance
117 Trials recovered from 2014-2018 covering 407229 patients
Ann of Intern Med, BMJ, JAMA, Lancet, NEJM
Circulation, Eur Heart J and JACC
Intervention Control
Loss to Follow-Up
Search
Overall loss to follow up at 2% 
Intervention : Control 
Event Ratio (1:1)
4%
Intervention : Control 
Event Ratio (3:1)
16%
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Extent of Loss to Follow- Up
Among the 117 included trials, 91 (78%) reported LTFU. 
Twenty- three trials reported no LTFU (20%), and 3 tri-
als did not report whether there was LTFU (3%). Of the 
trials with LTFU, the median percentage of LTFU was 
2% (interquartile range [IQR], 0.3%–4.8%) in the inter-
vention arm, 1.99% (IQR, 0.3%–5.4%) from the con-
trol arm, and 1.96% (IQR, 0.33%–5.3%) overall. The 
median difference between the intervention and the 
control groups was not significant (P=0.978; Figure 3).
The medians for the ratios of LTFU to events were 0.12 
(IQR, 0.03–0.33) in the intervention arm, 0.11 (IQR, 
0.02–0.42) in the control arm, and 0.11 (IQR, 0.03–
0.41) overall. A value of 0.12 means that ≈1 participant 
is LTFU when every 10 participants experience the 
primary outcome. However, the difference between 
the ratio of the intervention and the control groups was 
not significant (P=0.473; Figure 4).
Potential Impact of LTFU
Percentage of Trials Losing Significance
For the 4 common assumptions in which all 91 trials 
were included, the percentages of trials that lost signifi-
cance were 4% (no participants lost to follow- up had 
the event), 11% (all participants lost to follow- up had 
the event), 3% (best- case scenario), and 33% (worst- 
case scenario).
Considering the relative event incidence analysis 
method, Table 4 shows the percentage of eligible trials 
that lost significance across a range of assumptions 
for the event incidence among intervention and con-
trol arms (Figure 5). The percentage varied from 2% to 
16%. Figure 6 shows an inverse- proportion relation-
ship of the trials losing significance with the percent-
age of LTFU under the best and worst assumptions 
made by the relative event incidence analysis method.
Results of the prespecified sensitivity analysis on the 
subspecialties are reported (interventional cardiology 
versus others) in the online Data Supplement. There 
was a significant difference in the proportion of trials 
losing significance between interventional cardiology 
and other subspecialties (difference, 4.35% [95% CI, 
0.295%–8.41%]; P=0.0369; Figure S1 and Table S2).
DISCUSSION
We found considerable variation in the extent and re-
porting of LTFU data in contemporary cardiovascular 
clinical trials. We observed that certain characteristics 
of clinical trials—notably, inadequate or unclear allo-
cation concealment, length of follow- up, sample size, 
and type of intervention—were associated with in-
creased odds of LTFU. Importantly, the primary result 
Figure  6. Distribution of trials by LTFU proportion under 
the best and worst plausible assumptions made by using 
the relative event incidence for the control and intervention 
arms. 
Distribution of trials losing statistical significance stratified by 
the percentage of LTFU of the individual trial under the best 
and worst assumptions made by the more plausible relative 
event incidence method. An inverse- proportion relationship 
is shown in the graph, where there is higher number of trials 
losing significance in trials with lower proportions of LTFU. LTFU 
indicates loss to follow- up.
Table 5. Summary of the Important Common Issues for LTFU and Guidance in Conducting Trials and Reporting Trial Results
Issues That Should Be Noted Guidance
Inadequate or unclear allocation concealment If allocation concealment forms part of the trial design, then effective approaches to achieve 
allocation concealment include using a matched placebo (visually identical to the active 
treatment); central randomization (performed at a site remote from the trial’s location); 
sequentially numbered, sealed, opaque envelopes3
Large sample size and long follow up duration LTFU increases with larger trial sample size, hence investigators should be aware and 
mitigate the number of LTFU for increase in sample size and 1- y increase in duration
Reporting of LTFU Investigators should strive to reduce the number of LTFU. A CONSORT diagram should 
be included for readers. When LTFU has occurred, baseline characteristics, and extent of 
follow up duration before exclusion should be reported in the manuscript or supplement. The 
implications of LTFU should also be discussed in the manuscript. Time of dropout can be 
noted on a supplement or in the result paragraph or on the CONSORT diagram for readers 
to know the extent of follow up before dropout
CONSORT indicates Consolidated Standards of Reporting Trials; LTFU, loss to follow- up.
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in 1 of 6 trials might change if reasonable assumptions 
were made about the end point in patients with LTFU.
The inverse- proportion relationship noted in 
Figure 6 suggests that the impact of a small proportion 
of LTFU might be overlooked by investigators. More 
than one third of trials did not achieve effective blinding 
among either the participants or the site investigators. 
This finding is important because ineffective blinding 
is associated with overestimation of true treatment 
effects.135 Allocation concealment was inadequate or 
unclear in more than half of the trials. Conversely, an 
intention- to- treat analysis was used in 75% of trials, 
which minimizes the effects of attrition bias.3 Just over 
half of the trials included an explicit statement about 
LTFU, and >70% of the trials included a CONSORT 
flow diagram. Notably, baseline demographics on the 
LTFU participants were limited. Authors (93%) com-
monly omitted discussion of the potential impact or 
reasons for LTFU. We suggest that information on 
participants with LTFU should be included by authors 
in an appendix or in a defined column in a table of 
the trial participants’ characteristics (Table 5). Inverse 
probability weighting can be a helpful way of handling 
LTFU participants’ data, but it is not used in any of the 
included trials. Most trials did not impute data for LTFU 
participants. We noted a significant association be-
tween inadequate or unclear allocation concealment 
and increased odds of LTFU. This could be explained 
by less stringently implemented processes in trials with 
inadequate or unclear allocation concealment, includ-
ing suboptimal measures for following up participants.
Strengths and Weaknesses of the Study
Our study has several strengths. First, the forms for 
screening of the trials and related data collection 
were established before the start of the data col-
lection process. In addition, the calibration exercise 
was completed upfront as a preparatory step in-
tended to increase accuracy for the screening and 
data collection. Second, a range of assumptions 
was made for the participants with LTFU and ex-
plored the potential effect of LTFU on the estimate 
of the effect of the intervention, including whether 
or not the trial met statistical significance on its pri-
mary outcome and the change in the relative risk 
ratio and number of outcome events. The effect is 
focused on cardiovascular trials. Our analysis de-
pends on the accuracy and clarity of the included 
reports. Generalizability is also an issue. We focused 
our analysis on 8 journals’ publications during a 5- 
year period (2014–2018). A wider inclusion strategy 
with more journals (with lower impact factors) and 
trials with a nonsignificant primary outcome result 
might have returned different results. Our findings 
might underestimate the true effect of LTFU in the 
effect estimate if a wider range of RCTs were in-
cluded. Our review included trials with binary data 
only because of the design of the review analysis, 
which might further weaken the generalizability of 
the results. Time of dropout can be a factor influ-
encing the LTFU effect because early dropouts can 
influence the result to a larger extent than late drop-
outs. However, exact time of dropout is not noted in 
the reports, and we are unable to stratify the effect.
Implications
Investigators and sponsors should strive to reduce the 
number of participants with LTFU. The higher the LTFU, 
the more uncertainty increases around the treatment ef-
fect estimate and the potential for a false result. In the 
unfortunate event that LTFU happened, its impact can 
be estimated using the worst assumption (Data S7). As 
for the reporting of LTFU, editors may consider requir-
ing authors to provide a fully informative and transpar-
ent report on participant LTFU including the inclusion 
and exclusion criteria of patients, which is in line with 
CONSORT guidelines. Specifically, investigators should 
provide information on participants with LTFU including 
their baseline characteristics, reasons for LTFU, and du-
ration of follow- up before exclusion and then compared 
with those who completed follow- up. This information 
could be published as an appendix. Implications of 
LTFU should be discussed when LTFU has occurred 
(Table  5). This review provides estimates of the prob-
ability that the primary analysis of cardiovascular trials 
could lose statistical significance when LTFU events are 
taken into account by making appropriate estimate of 
event incidence. Although the 4 less plausible but com-
monly used assumptions may not eventuate, they can 
be taken as the upper limit of change in trial significance. 
Early LTFU has a more influential effect on the analysis 
than late LTFU near the overall study duration, which 
highlighted the need for investigators to stratify LTFU by 
follow- up extent. Future studies can look at the extent of 
change in treatment effect in relation to the LTFU pro-
portion and event number and the effect of partial and 
full LTFU defined as difference in the extent of follow-
 up before exclusion. The influence of dropout time on 
LTFU effect can be explored for assessing the possibil-
ity of systemic inclusion of patients accounting for early 
dropouts.
CONCLUSIONS
Almost 1 in 6 (16%) cardiovascular randomized trials 
published in leading journals may have a change in the 
primary outcome if plausible assumptions are made 
about differential event rates of participants lost to fol-
low- up. There is scope for improvement arising from 
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LTFU in randomized trials in cardiovascular medicine. 
Bias minimization through mitigation of participants 
lost to follow- up offers the opportunity to enhance the 
value of randomized trials.
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Data S1 - Hierarchy of outcomes relative to patient importance in FLUKE   
I. Mortality 
a. All-cause mortality 
b. Disease specific mortality 
II. Morbidity 
a. Cardiovascular major morbid events 
b. Other major morbid events (e.g. Revascularization) 
c. Onset/recurrence/relapse/remission of diseases  
d. Hospitalization, medical and surgical procedures 
e. Infections 
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Data S2- Search strategy for Medline and Embase using OVID interface  
Medline 
1 exp Myocardial Ischemia/ 
2 (MYOCARD$4 adj4 (ISCHAEMI$2 or ISCHEMI$2)).tw. 
3 exp Coronary Artery Bypass/ 
4 ((ISCHAEMI$2 or ISCHEMI$2) adj4 HEART).tw. 
5 CORONARY.ti,ab. 
6 exp Coronary Disease/ 
7 exp Myocardial Revascularization/ 
8 exp Myocardial Infarction/ 
9 (MYOCARD$5 adj4 INFARCT$5).tw. 
10 (HEART adj4 INFARCT$5).tw. 
11 exp Angina Pectoris/ 
12 ANGINA.tw. 
13 exp Heart Failure/ 
14 (HEART adj6 Failure).tw. 
15 or/1-14 
16 exp Heart Diseases/ 
17 (Heart adj4 disease$2).tw. 
18 MYOCARD$5.tw. 
19 CARDIAC$2.tw. 
20 CABG.tw. 
21 PTCA.tw. 
22 (STENT$4 and HEART).tw. 
23 Heart Bypass, Left/ or Heart Bypass, Right/ 
24 CARDIOLOGY SERVICE, HOSPITAL/ or CARDIOLOGY/ 
25 or/16-24 
26 15 or 25 
27 Randomized controlled trial.pt. 
28 randomized controlled trial/ 
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29  (random$ or placebo$).ti,ab,sh. 
30  ((singl$ or double$ or triple$ or treble$) and (blind$ or mask$)).tw,sh. 
31  or/27-30 
32 (retraction of publication or retracted publication).pt. 
33 31 or 32  
34 (ANIMALS not HUMANS).sh. 
35 33 not 34 
36 35 and 26 
37 bmj.jn 
38 “Annals of Internal Medicine”.jn. 
39 jama.jn. 
40 lancet.jn. 
41 “new england journal of medicine”.jn. 
42 36 and 37 
43 36 and 38 
44 36 and 39 
45 36 and 40  
46 36 and 41 
47 european heart journal.jn. 
48 circulation.jn. 
49 journal of the American college of cardiology.jn. 
50 36 and 47 
51 36 and 48 
52 36 and 49 
53 42 or 43 or 44 or 45 or 46 or 50 or 51 or 52  
54 limit 53 to yr=”2014-2018” 
 
 
 
 
D
ow
nloaded from
 http://ahajournals.org by on A
ugust 5, 2020
 
EMBASE 
1 Heart Disease/ 
2 (MYOCARD$4 adj2 (ISCHAEMI$2 or ISCHEMI$2)).tw. 
3 ((ISCHAEMI$2 or ISCHEMI$2) adj4 HEART).tw. 
4 Coronary Artery Disease/ 
5 Transluminal Coronary Angioplasty/ 
6 (CORONARY adj4 (DISEASE$2 or BYPASS$2 or THROMBO$5 or ANGIOPLAST$2)).tw. 
7 Heart Infarction/ 
8 (MYOCARD$4 adj2 INFARCT$5).tw. 
9 (HEART adj2 INFARC$5).tw. 
10 Heart Muscle Revascularization/ 
11 Angina Pectoris/ 
12 ANGINA.tw. 
13 (HEART adj2 FAILURE).tw. 
14 (HEART adj2 DISEASE$2).tw. 
15 CARDIAC$2.tw. 
16 CABG.tw. 
17 PTCA.tw. 
18 (STENT$4 and HEART).ti,ab. 
19 Extracorporeal Circulation/ 
20 cardiology/ 
21 or/1-20 
22 Randomized Controlled Trial/ 
23 Single Blind Procedure/ 
24 Double Blind Procedure/ 
25 Crossover Procedure/ 
26 22 or 23 or 24 or 25 
27 (random$ or factorial$ or crossover$ or placebo$ or (cross adj over) or assign$).ti,ab. 
28 ((singl$ or double$ or triple$ or treble$) and (blind$ or mask$)).ti,ab. 
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29 controlled clinical trial*.ti,ab. 
30 28 or 26 or 27 or 29 
31 21 and 30 
32 (animal$ not human$).sh,hw. 
33 31 not 32 
34 bmj.jn 
35 “Annals of Internal Medicine”.jn. 
36 jama.jn. 
37 lancet.jn. 
38 “new england journal of medicine”.jn. 
39 european heart journal.jn. 
40 circulation.jn. 
41 journal of the American college of cardiology.jn. 
42 33 and 34 
43 33 and 35 
44 33 and 36 
45 33 and 37  
46 33 and 38  
47 33 and 39 
48 33 and 40 
49 33 and 41 
50 or/42-46 
51 or/47-49 
52 limit 51 to article or article in press or conference paper  
53 50 or 52 
54 limit 53 to yr =”2014-2018” 
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Data S3 – FLUKE study data screening form  
FLUKE study: Data Screening Form 
 
Screener initials:                              Study ID:                          Author, year:                                ,  
Journal:          ⁪ AIM             ⁪ BMJ            ⁪ JAMA          ⁪ Lancet         ⁪ NEJM 
 
 
1.  Eligible RCT Report?                         ⁪ No                                            ⁪ Exclude  stop here 
⁪ Yes, type of 
RCT: 
⁪ Two arms                                   ⁪ Multiple Arms 
⁪ Factorial design                           
 
 
2.  Trial described as:                        ⁪ Non-inferiority 
      ⁪Equivalence 
       ⁪Neither 
 
 
3.  Primary outcome clearly specified.    ⁪ Yes, one:                                                                 (go to q5) 
               ⁪ No, multiple primary outcomes:                                        (go to q4) 
    ⁪ None specified (go to q4) 
 
 
4.  If multiple or no primary outcome specified, select one :    
 
 
5.  Primary outcome category # (refer to the guide):                                                    (e.g.  II.3) 
 
 
6.  Effect on primary endpoint reported as:    ⁪ Continuous outcome exclusively                              
⁪ Exclude 
⁪ Multinomial outcome exclusively                              ⁪ Exclude 
⁪ Binary outcome expressed as rate exclusively         ⁪ Exclude 
⁪ Binary outcome, data not available for 2x2 table      ⁪ Exclude 
⁪ Binary outcome, data available for 2x2 table, go to the next question 
 
 
7.  Is it a composite endpoint?             ⁪ Yes, list components:   
⁪ No 
 
 
8.  Is it a patient important outcome?         
         ⁪ No   ⁪ Exclude 
         ⁪ Yes, go to the next question 
 
 
9.  Result statistically significant?       ⁪ No   ⁪ Exclude 
⁪Yes
Please fill out this box for each study 
 
 
      ⁪ Include in FLUKE 
 
      ⁪ Exclude from FLUKE 
 
     ⁪ 3rd reviewer needed 
        (no consensus between 2 reviewers) 
If exclude, reason for exclusion: 
⁪ Not RCT 
⁪ Not eligible RCT 
⁪ Data for the primary endpoint not 
available for 2x2 table 
1           ⁪ Outcome not patient important 
⁪ Result not statistically significa
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Data S4 – FLUKE study data abstraction form  
FLUKE study: Data Abstruction Form 
 
Screener initials:                              Study ID:                          Author, year:                                ,  
Journal:          ⁪ AIM             ⁪ BMJ            ⁪ JAMA          ⁪ Lancet         ⁪ NEJM 
 
 
1.  Eligible RCT Report?                         ⁪ No                                            ⁪ Exclude  stop here 
⁪ Yes, type of 
RCT: 
⁪ Two arms                                   ⁪ Multiple Arms 
⁪ Factorial design                           
 
 
2.  Trial described as:                        ⁪ Non-inferiority 
      ⁪Equivalence 
       ⁪Neither 
 
 
3.  Primary outcome clearly specified.    ⁪ Yes, one:                                                                 (go to q5) 
               ⁪ No, multiple primary outcomes:                                        (go to q4) 
    ⁪ None specified (go to q4) 
 
 
4.  If multiple or no primary outcome specified, select one :    
 
 
5.  Primary outcome category # (refer to the guide):                                                    (e.g.  II.3) 
 
 
6.  Effect on primary endpoint reported as:    ⁪ Continuous outcome exclusively                              
⁪ Exclude 
⁪ Multinomial outcome exclusively                              ⁪ Exclude 
⁪ Binary outcome expressed as rate exclusively         ⁪ Exclude 
⁪ Binary outcome, data not available for 2x2 table      ⁪ Exclude 
⁪ Binary outcome, data available for 2x2 table, go to the next question 
 
 
7.  Is it a composite endpoint?             ⁪ Yes, list components:   
⁪ No 
 
 
8.  Is it a patient important outcome?         
         ⁪ No   ⁪ Exclude 
         ⁪ Yes, go to the next question 
 
9.  Result statistically significant?       ⁪ No   ⁪ Exclude 
⁪Yes
Please fill out this box for each study 
 
 
      ⁪ Include in FLUKE 
 
      ⁪ Exclude from FLUKE 
 
     ⁪ 3rd reviewer needed 
        (no consensus between 2 reviewers) 
If exclude, reason for exclusion: 
⁪ Not RCT 
⁪ Not eligible RCT 
⁪ Data for the primary endpoint not 
available for 2x2 table 
1           ⁪ Outcome not patient important 
⁪ Result not statistically significant 
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Background Information 
10. Mean/Median Age 
Number of study centers 
Age= 
N= 
11. Funding  
Check all that apply  
⁪ Private only for profit, other 
⁪ Private not fro profit  
⁪ Government  
⁪ Not funded  
⁪ Not reported  
12. Clinical Area  
Check only one  
⁪ Medical  
⁪Pharmacological 
⁪ Surgical  
⁪Electrophysiology 
⁪Heart failure  
⁪Interventional cardiology 
⁪Open heart surgery  
⁪General cardiology 
⁪Cardiovascular imaging 
⁪ Others 
 
 
13. Intervention 
Check only one  
⁪ Pharmacological  
⁪ Surgery  
⁪ Rehabilitation 
⁪ Behavioral intervention 
⁪ Complementary and alternative medicine 
⁪ Diagnostic test  
⁪ Other (specify) 
14. Control 
Check only one  
⁪Standard care  
⁪Placebo  
⁪Pharmacological  
⁪Surgery  
⁪Rehabilitation 
⁪Behavioral intervention   
⁪Diagnostic test  
⁪Other (specify)  
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Methodological Quality  
15. Concealment of Allocation  
Check only one  
⁪ Adequate (involving the use of sequentially numbered, 
opaque, sealed envelope or coded medication containers or 
central randomization or quasi-randomized) 
⁪ Inadequate (Like Open random allocation schedule) 
⁪No method described  
⁪Not concealed  
⁪Not reported  
16. Blinding of patients ⁪Adequate  
⁪Inadequate  
⁪Not reported  
17. Blinding of health care providers ⁪Adequate  
⁪Inadequate  
⁪Not reported 
18. Blinding of data collectors ⁪Adequate  
⁪Inadequate  
⁪Not reported 
19. Blinding of outcome adjudicators ⁪Adequate  
⁪Inadequate  
⁪Not reported 
20. Blinding of data analysts ⁪Adequate  
⁪Inadequate  
⁪Not reported 
21. Study stopped early for benefit  ⁪Yes 
⁪No 
 
ITT Principle  
22. Authors used the term ITT  ⁪ Yes, ITT  
⁪ Yes, Modified ITT 
⁪ No   
23. Post randomization exclusion of 
mistakenly randomized  
⁪Yes (Skip Question 24 and 25) 
⁪No  (Go to question 24 and 25) 
⁪Not reported  
24. Information about ineligibility was 
available at randomization  
⁪Yes 
⁪No 
⁪Not reported 
25. Post randomization exclusions were 
blinded to allocation  
⁪Yes 
⁪No 
⁪Not reported 
26. Patients for whom outcome data is 
available were analyzed in the arm 
to which they were randomized  
⁪Yes 
⁪No 
⁪Not reported 
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LTFU statements  
27. LTFU explicitly reported  
 
⁪ Explicit statement: LTFU occurred 
⁪ Explicit statement: LTFU did not occur 
⁪ No explicit statement about LTFU    
28. CONSORT flow diagram  ⁪CONSORT diagram showing LTFU  
⁪CONSORT diagram not showing LTFU 
⁪No CONSORT diagram  
29. For studies with no explicit 
statement about LTFU and no 
consort diagram  
⁪Meet all 3 prespecified criteria  
⁪ Does not meet all 3 prespecified criteria  
⁪N/A 
30. LTFU reported separately for the 
2 arms  
⁪Yes 
⁪No 
31. Authors compared baseline 
characteristics of LTFU  
⁪Yes  
⁪No 
32. Implications of LTFU discussed   ⁪Yes 
⁪No 
33.  Methods of dealing with LTFU 
explicitly described  
⁪Yes, methods 
⁪Yes, results  
⁪No  
  
 
Methods of dealing with LTFU   
34 Methods 
  
 Not applicable, no LTFU occurred ⁪ 
Not applicable, uncertain whether LTFU occurred  ⁪ 
Unclear which method used  ⁪ 
Survival analysis  ⁪ 
Complete case analysis  ⁪ 
Worst case scenario ⁪ 
Best case scenario  ⁪ 
None of the LTFU had the outcome  ⁪ 
All the LTFU had the outcome  ⁪ 
Different methods for different subgroups of LTFU  ⁪ 
Other (specify) ⁪ 
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LTFU statistical data     
Primary outcome data  Intervention control total Prespecified 
assumptions 
for different 
groups of 
LTFU 
35. Mistakenly randomized, inappropriately 
excluded (subtotal 1) 
    
36. Did not receive intervention, 
inappropriately excluded (subtotal 2)  
 
    
37. Withdrew consent (subtotal 3)  
⁪unclear whether followed up  
⁪not followed up  
⁪followed up, not included in the analysis (not LTFU 
for FLUKE)  
    
38. Withdrew consent due to side effect or 
adverse event   
    
39. Withdrew consent due to other 
specified reason 
    
40. Withdrew consent due to unclear 
reason  
    
41.  Cross over (subtotal 4)  
⁪unclear whether followed up  
⁪not followed up  
⁪followed up, not included in the analysis (not LTFU 
for FLUKE) 
⁪followed up, analyzed in a group not randomized to 
(not LTFU for FLUKE) 
    
42. Cross over due to side effect or 
adverse event   
    
43. Cross over due to other specified 
reason 
    
44. Cross over due to unclear reason     
45. Non adherent (subtotal 5)  
⁪unclear whether followed up  
⁪not followed up  
⁪followed up, not included in the analysis (not LTFU 
for FLUKE) 
⁪followed up, analyzed in a group not randomized to (not 
LTFU for FLUKE) 
    
46. Non adherent due to side effect or 
adverse event   
    
47. Non adherent due to other specified 
reason 
    
48. Non adherent due to unclear reason     
49. Lost contact and no other source of outcome data      
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50. Others     
51. LTFU total     
 
 
LTFU statistical data 
    
Primary outcome data  Intervention control total  
52. Mistakenly randomized, inappropriately 
excluded (subtotal 1) 
    
53. Did not receive intervention, 
inappropriately excluded (subtotal 2)  
 
    
54. Randomized       
55. Randomized adjusted (54-53-52)       
Primary outcome data Intervention 
events  
Control 
events 
  
39. Included in primary analysis      
40. Unadjusted effect estimate;95% CI; P 
value   
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Data S5: Further elaboration on the methodology adopted in the systematic review  
Analysis method  
a. Assessment on the methodological and reporting quality 
Bikdeli et al first reported a set of risk factors to consider when evaluating methodological and 
reporting quality of trials in 2019.14 We consider limiting factors to include the following:  
1. Inadequate allocation sequence concealment  
2. No blinding on patient  
3. Early stoppage 
4. Not using intention-to-treat analysis  
5. Absence of protocol 
6. Without explicit statement on the status of loss to follow up  
A univariable random-effects meta-regression analysis was conducted using the log odds of 
participants lost to follow-up as the dependent variable and general trial characteristics and 
methodological characteristics as independent variables 
1. General trial characteristics  
a. Number of centres  
b. Sample size  
c. Length of follow-up  
d. Type of intervention (Surgery/interventional vs other) 
e. Cardiology Subspecialty (General Medical vs Others) 
f. Type of funding (Commercial Vs Non-profit organisations, governmental or none) 
2. Methodological trial characteristics 
a. Concealment of allocation  
b. Blinding of patients 
c. Stopping early for benefit  
d. Use of intention to treat analysis  
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b. Extent of loss to follow-up  
The extent of LTFU was estimated by calculating the percentage of LTFU in each trial from each arm 
(intervention and control). Then, median and interquartile range of the percentages across trials were 
obtained. A ratio of the total number of participants identified as LTFU to the number of primary 
outcome events was calculated for each trial (the “lost to follow-up to events ratio”). Median and 
standard deviation of this ratio was also calculated across the trials.  
 
c. Potential impact of loss to follow-up  
The potential impact of LTFU is evaluated by proposing assumptions about the outcomes of participants 
LTFU and the estimated effect of that assumption on the primary outcome (Data S6 for examples). The 
following common assumptions are first used for calculation: 
a. None of the participants lost to follow-up had the event  
b. All the participants lost to follow-up had the event  
c. None of those lost to follow-up in the treatment group had the event and all those lost 
to follow-up in the control group did (best case scenario) 
d. All participants lost to follow-up in the treatment group had the event and none of those 
in the control group did (worst case scenario) 
Although the above assumptions are widely used in multiple literatures, some experts have countered 
they are not plausible and have suggested a novel method for estimating effects of LTFU.17 Akl et al 
evaluated more plausible assumptions that the incidence of events among participants lost to follow-up 
is higher by a specific ratio relative to the observed event incidence among participants followed up. 17 
They defined RILTFU/FU as the event incidence among those lost to follow-up relative to the event 
incidence among those followed up and made plausible assumptions towards the outcome of LTFU 
participants (see data S6). LTFU refers to “lost to follow-up” and FU refers to “followed up”. A range 
of plausible RILTFU/FU values (1,1.5,2,3) was used in both the intervention group and the control group. 
3 is the upper limit, which was previously determined by consensus. 17  
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Data S6 - Illustrations of the assumptions being considered in FLUKE with examples 
 
Examples based on the following theoretical trial: 
- Randomization: 100 to intervention while 100 to control group  
- Loss to follow up: 20 in the intervention group while 10 in the control group  
- Events: 15 in the intervention group while 20 in the control group 
 
Assumption 1: None of the lost to follow-up participants had the event  
  intervention Control  
a Lost to follow up 20 10 
b Events assumed* 0 0 
c Events observed in the trial  15 20 
d Total events (b+c) 15 20 
e Randomized  100 100 
f Risk (d/e) 0.15 0.2 
g Relative risk  0.75 
*None of the lost to follow-up in either group had an event  
 
Assumption 2: All lost to follow-up participants had the event  
  intervention Control  
a Lost to follow up 20 10 
b Events assumed* 20 10 
c Events observed in the trial  15 20 
d Total events (b+c) 35 30 
e Randomized  100 100 
f Risk (d/e) 0.35 0.3 
g Relative risk  1.17 
*Each of the lost to follow-up both groups had an event  
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Assumption 3: Best case scenario  
  intervention Control  
a Lost to follow up 20 10 
b Events assumed* 0 10 
c Events observed in the trial  15 20 
d Total events (b+c) 15 30 
e Randomized  100 100 
f Risk (d/e) 0.15 0.3 
g Relative risk  0.5 
* None of those lost to follow up in the treatment group had the event and all those lost to 
follow up in the control group did 
 
Assumption 4: Worst case scenario 
  intervention Control  
a Lost to follow up 20 10 
b Events assumed* 20 0 
c Events observed in the trial  15 20 
d Total events (b+c) 35 20 
e Randomized  100 100 
f Risk (d/e) 0.35 0.2 
g Relative risk  1.75 
* All participants lost to follow up in the treatment group had the event and none of those in 
the control group did 
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Assumptions using relative event incidence (RILTFU/FU) 
 
RILTFU/FU refers to the event incidence among those lost to follow-up (LTFU) relative to the 
event incidence among those followed up (FU) 
 
RILTFU/FU = (Number of events among LTFU / number of LTFU) / (Number of events among 
FU / number of FU) 
- RILTFU/FU =1; the event incidence among LTFU and FU is equal  
- RILTFU/FU >1; the event incidence among LTFU is greater than that of FU 
 
Assumption 1: RILTFU/FU = 1 in intervention group; and RILTFU/FU = 3 in control group 
  intervention Control  
a Lost to follow up 20 10 
b Events assumed* (20)(1)(15/80)=4 (10)(3)(20/90)=7 
c Events observed in the trial  15 20 
d Total events (b+c) 19 27 
e Randomized  100 100 
f Risk (d/e) 0.19 0.27 
g Relative risk  0.70 
* Number of events assumed= (number lost to follow up) x (RILTFU/FU) x (Events 
observed/(number randomized – number lost to follow up)) 
 
 
Assumption 2: RILTFU/FU = 3 in intervention group; and RILTFU/FU = 1.5 in control group 
  intervention Control  
a Lost to follow up 20 10 
b Events assumed* (20)(3)(15/80)=11 (10)(1.5)(20/90)=3 
c Events observed in the trial  15 20 
d Total events (b+c) 26 23 
e Randomized  100 100 
f Risk (d/e) 0.26 0.23 
g Relative risk  1.13 
* Number of events assumed= (number lost to follow up) x (RILTFU/FU) x (Events 
observed/(number randomized – number lost to follow up)) 
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Data S7 – Estimation method accounting for LTFU  
Assumptions made using relative event incidence (RILTFU/FU) 
 
RILTFU/FU refers to the event incidence among those lost to follow-up (LTFU) relative to the 
event incidence among those followed up (FU) * 
 
Worst RILTFU/FU assumption = 3 in intervention arm 1 in control arm 
 
Assumption: RILTFU/FU = 3 in intervention group; and RILTFU/FU = 1 in control group * 
  Intervention Control  
a Number of Lost to follow up X Y 
b Event Rate (ER) (Intervention Event / Number 
of participants in intervention) 
(Control Event/ Number of 
participants in control) 
c Events assumed† (X)(3)(ER inter) = m (Y)(1)(ER contr) = n 
d Events observed in the trial  Intervention Event Control Event 
e Total events (c+d) m + Intervention Event n + Control Event 
f Randomized  Number of participants in 
intervention 
Number of participants in 
control 
G Risk (e/f) R inter R contr 
h Relative risk  R inter / R contr 
* RI LTFU/FU = (Number of events among LTFU / number of LTFU) / (Number of events 
among FU / number of FU) 
- RI LTFU/FU =1; the event incidence among LTFU and FU is equal  
- RI LTFU/FU >1; the event incidence among LTFU is greater than that of FU 
 
† Number of events assumed= (number lost to follow up) x (RILTFU/FU) x (Events 
observed/(number randomized – number lost to follow up)) 
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Data S8 – Among the 23 trials from intervention cardiology, percentage which results 
would lose significance under different assumptions:  
• No events experienced by any lost to follow-up participants =0% 
• Events experienced by all the lost to follow-up participants =17% 
• Events only experienced by the LTFU in control group while no events experienced by 
the LTFU in treatment group (best case scenario) =0% 
• Events only experienced by the LTFU in treatment group while no events experienced 
by the LTFU in control group (worst case scenario) =22% 
 
Among the 68 trials from other cardiology field, percentage which results would lose 
significance under different assumptions:  
• No events experienced by any lost to follow-up participants =6% 
• Events experienced by all the lost to follow-up participants =9% 
• Events only experienced by the LTFU in control group while no events experienced by 
the LTFU in treatment group (best case scenario) =4% 
• Events only experienced by the LTFU in treatment group while no events experienced 
by the LTFU in control group (worst case scenario) =37%  
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Table S1 – Reference list of the 117 studies included in FLUKE   
Study reference  Country  Journal Mean age  
S. Verheye (2015) 123 Belgium NEJM 67.8 
S. S. Anand (2018) 20 Canada The Lancet 67.8 
M. Dewey (2016) 42 Germany BMJ 60.4 
HPS/TIMI55- REVEAL Group 
(2017) 28 UK NEJM 67 
ASCEND Study Group (2018) 29 UK NEJM 63.2 
H. Calkins (2017) 32 
Germany NEJM 59.2 
C. P. Cannon (2017) 33 
USA NEJM 70.8 
Stuart J Connolly (2018) 37 
Canada The Lancet 68.3 
P J Devereaux (2018) 41 
Canada The Lancet 70 
J.W. Eikelboom (2018) 48 
Canada NEJM 68.2 
R. Estruch (2018) 50 
Spain NEJM 67 
C. M. Gibson (2016) 54 
USA NEJM 70.1 
E. J. Velazquez (2016) 122 
USA NEJM 59.5 
J. P. Greenwood (2016) 57 
UK JAMA 56.3 
Q. Zhao (2018) 133 
China JAMA 63.6 
B. P Halliday (2018) 59 
UK The Lancet 55 
A. F. Hernandez (2018) 62 
USA The Lancet 64.1 
S. C. Johnston (2018) 69 
USA NEJM 65 
W.N. Kernan (2016) 73 
USA NEJM 63.5 
JM. Kim (2018) 74 
South Korea JAMA 60 
S. Yusuf (2016) 129 
Canada NEJM 65.7 
N. F. Marrouche (2018) 78 
USA NEJM 64 
S. P. Marso (2016) 79 
USA NEJM 64.3 
J. L. Mas (2017) 80 
France NEJM 43.7 
M.  S. Maurer (2018) 82 
USA NEJM 75 
D. E Kandzari (2017) 72 
USA The Lancet 64.5 
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M.R. Mehra (2018) 84 
USA NEJM 60 
M. R. Mehra (2016) 85 
USA NEJM 59.6 
M.E. Wechsler (2017) 124 
USA NEJM 48.5 
A. N Patel (2016) 92 
USA The Lancet 65 
G.D. Perkins (2018) 93 
UK NEJM 69.7 
S. R. Steinhubl (2018) 110 
USA JAMA 72.3 
P.M. Ridker (2017) 97 
USA NEJM 61 
M. Valgimigli (2015) 119 
Netherlands The Lancet 65.8 
M. S. Sabatine (2017) 100 
USA NEJM 63 
J. L. Sapp (2016) 102 
Canada NEJM 68.6 
J. L. Saver (2017) 104 
USA NEJM 45.9 
G.G. Schwartz, (2018) 105 
USA NEJM 58.6 
P. C. Smits (2017) 107 
Netherlands NEJM 61.3 
B. Zinman (2015) 134 
Canada NEJM 63.1 
L. Søndergaard (2017) 109 
Denmark NEJM 45.2 
G.W. Stone (2018) 111 
USA NEJM 72.3 
N. Tegn (2016) 114 
Norway The Lancet 84.8 
H. Thiele (2017) 115 
Germany NEJM 70 
M. Valgimigli (2018) 118 
Switzerland The Lancet 65.8 
O. Varenne (2017) 121 
France The Lancet 81.4 
S. Yusuf (2016) 128 
Canada NEJM 65.7 
A. Zarbock (2015) 130 
Germany JAMA 70.4 
S.D. Wiviott (2018) 125 
USA NEJM 79.9 
M. Abdel-Wahab (2014) 18 
Germany JAMA 80.8 
D. H. Adams (2014) 19 
USA NEJM 83.3 
A. Appelboam (2015) 21 
UK The Lancet 54.8 
M. P. Bonaca (2015) 25 
USA NEJM 65.3 
S. S Brar (2014) 30 
USA The Lancet 71.5 
C. P. Cannon (2015) 34 
USA NEJM 63.6 
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B. De Bruyne (2014) 40 
Belgium  NEJM 63.7 
J. D. Douketis (2015) 47 
USA NEJM 71.7 
T. Engstrøm (2015) 49 
Denmark The Lancet 63.5 
A. M. Gillinov (2015) 55 
USA NEJM 69.6 
D. J. Gladstone (2014) 63 
Canada NEJM 72.8 
THE SPRINT Research Group 
(2015) 126 
USA NEJM 67.9 
Y. Han (2015) 60 
China JAMA 57.7 
G. Hindricks (2014) 63 
Germany  The Lancet 65.5 
SJ Hong (2015) 64 
Korea JAMA 64 
Y. Huo (2015) 65 
China JAMA 60 
M. Imazio (2014) 66 
Italy The Lancet 48.8 
M. Imazio (2014) 67 
Italy JAMA 67.5 
J. J. McMurray (2014) 83 
UK NEJM 63.8 
G. Meyer (2014) 86 
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Table S2- Sensitivity analysis of the percentage of eligible trials on intervention cardiology vs trials on other subjects in which results 
would lose significance under different assumptions on the LTFU outcomes on intervention and control group 
Intervention Cardiology † Others † 
N=23 RI LTFU/FU (Control) * N=68 RI LTFU/FU (Control) * 
3 2 1.5 1  3 2 1.5 1 
RI LTFU/FU (intervention) * RI LTFU/FU (intervention) * 
1 9 9 0 0 1 1 1 3 6 
1.5 9 0 0 0 1.5 1 3 4 6 
2 9 0 0 0 2 3 5 6 16 
3 0 0 0 0 3 4 12 13 22 
N= Number 
* RI LTFU/FU is the relative event incidence among those lost to follow-up compared with those followed up  
† Paired T test shows that there is significant difference between the subgroup across different assumptions (Mean difference =4.35% ,95%CI 0.295%-8.41%, 
p=0.0369) 
 
  
D
ow
nloaded from
 http://ahajournals.org by on A
ugust 5, 2020
20 
 20 
Figure S1- Scatterplot of the proportion of trials losing significance based on various 
assumption stratified by subspecialty  
 
 
Legend-  CI = Confidence Interval; Diff = Difference; LTFU = Lost to follow up; p = p-value 
Figure S1 shows the proportion of trials losing significance based on each assumption. It is 
grouped by the different type of subspecialty. A mean of 3.75% trials form the interventional 
cardiology subspecialty lost significance while 8.1% trials from other subspecialty lost 
significance. A paired sample t test was run against the subspecialty yielding a significant 
difference in proportions (p-value = 0.0.0369) 
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